Breast cancer 21 gene test guides precise treatment

Share This Post

Breast cancer problem

Breast cancer is a common female malignant tumor that seriously threatens the physical and mental health of women, so it is also known as the “red killer”. Statistics show that breast cancer causes 458,000 deaths each year, and its incidence is increasing worldwide. In recent years, the incidence of breast cancer in India has risen rapidly, and there is a trend of youth. Breast cancer has become the most common cancer among Indian women. The number of new breast cancers and deaths in India each year account for 12.2% and 9.6% of the world’s total. 

Breast cancer treatment

Breast cancer is not terrible. Breast cancer treatment has achieved rapid progress. Breast cancer is one of the best treatments for breast cancer. According to statistics, the five-year survival rate for breast cancer in the United States is 89%, and the five-year survival rate for breast cancer patients in China is 73.1%. We can treat breast cancer as a chronic disease, not a terminal illness.

The treatment of breast cancer is mainly surgery + chemotherapy or radiotherapy. The conventional treatment is to remove the tumor lesion as much as possible. After the operation, radiotherapy and chemotherapy are used to kill the residual tumor cells and prevent tumor recurrence. However, scientific research shows that not all breast cancer patients need chemotherapy, and chemotherapy is not useful for some breast cancer patients. Unwanted chemotherapy also kills a large number of normal human cells, which is extremely harmful to women. Breast cancer gene tests invented by American scientists can help breast cancer patients avoid unnecessary chemotherapy. The occurrence, development, and metastasis of breast cancer are related to gene mutations. Breast cancer 21 gene testing can find these mutant genes, predict the probability of breast cancer patients’ recurrence, and help breast cancer patients choose or avoid chemotherapy. The whole-gene cancer test can screen targeted drugs to treat this mutation, to achieve the largest curative effect and the smallest toxic and side effects, and to achieve precise personalized treatment.

Genetic testing in breast cancer

Breast 21 oncogene testing can help doctors and patients decide on the best treatment options. Through the 21-gene test, observe the interaction between genes to determine the characteristics of the tumor, so as to predict the probability of breast cancer recurrence and the probability of possible benefit from chemotherapy. In other words, patients can know whether their breast cancer will recur through genetic testing, the probability of recurrence, determine whether breast cancer patients need postoperative chemotherapy, and how to avoid excessive chemotherapy. In order to determine more effective treatment options for breast cancer patients, to achieve sophisticated individualized treatment.

Breast cancer 21 gene test is beneficial for patients with early estrogen receptor positive (ER +), negative lymph node metastasis, and newly diagnosed breast cancer patients who will be treated with tamoxifen. It can predict the probability of breast cancer recurrence and the possibility of chemotherapy Benefit probability. After menopause, lymph node-positive and estrogen receptor-positive invasive breast cancer patients can also be genetically tested to determine whether the patient needs chemotherapy.

In recent years, through genetic testing to guide precise treatment, the 5-year survival rate and long-term survival rate of breast cancer patients have greatly improved. Breast cancer has become one of the solid tumors with the best curative effect.

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Donor T cells for CAR T cell therapy
CAR T-Cell therapy

Donor T cells for CAR T cell therapy

Donor-derived (allogeneic) CAR T cell therapy provides a scalable, affordable substitute for patient-specific (autologous) treatment, offering “off-the-shelf” therapy for cancer patients. Although difficulties such as graft-versus-host disease (GvHD) and immune rejection are present, developments in gene editing, immune evasion strategies, and universal donor cells are leading the way. With continuous clinical trials and creative approaches, allogeneic CAR T cells may transform cancer therapy, enabling lifesaving treatment to be more accessible and efficient.

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies Experience from China
CAR T-Cell therapy

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Experience from China

China has made significant strides in optimizing chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Key strategies include improving CAR design to enhance efficacy and reduce toxicity, optimizing manufacturing processes for scalability, and refining patient selection criteria. Researchers are integrating novel gene-editing techniques and combination therapies to overcome resistance. Additionally, real-world data from Chinese hospitals emphasize the importance of standardized protocols and cost-effective production for broader accessibility.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟